CureVac N.V. CVAC NASDAQ

CureVac N.V. (CVAC) reported total assets of $802.83M and total liabilities of $106.22M for fiscal year 2024, resulting in total equity of $696.61M.

The company held $485.37M in cash and short-term investments. Total debt stood at $38.97M, with net debt of $-442.78M. The Debt-to-Equity (D/E) ratio was 0.06 (conservative).

Current ratio is 7.28, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.06, current ratio of 7.28 — balance sheet is strong
• MOAT (70/100) — Total assets $802.83M and equity $696.61M support the company's competitive scale
• VALUE (78/100) — Debt-to-Equity 0.06 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 73/100 with 5/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

RHHBF

Roche Holding AG

$418.50

+1.82%

RHHBY

Roche Holding AG

$51.02

+0.65%

AZN

AstraZeneca PLC

$204.38

+1.06%

NVSEF

Novartis AG

$156.48

+0.00%

MRK

Merck & Co., Inc.

$119.96

-0.16%